48
Participants
Start Date
December 15, 2024
Primary Completion Date
November 15, 2026
Study Completion Date
November 15, 2028
JAK1 Inhibitor
Golidocitnib 150mg QD orally, with a 28-day cycle. Efficacy will be evaluated once per cycle during the first year, and once every two cycles thereafter. Treatment will continue for up to 24 cycles, or until disease progression, lack of response within the first 6 cycles, or the occurrence of intolerable toxicity, whichever occurs first
RECRUITING
Institute of Hematology & Blood Diseases Hospital, China, Tianjin
NOT_YET_RECRUITING
Institute of Hematology & Blood Diseases Hospital, Tianjin
Tianjin First Central Hospital
OTHER
The First Affiliated Hospital of Air Force Medicial University
OTHER
The First Hospital of Jilin University
OTHER
The First Affiliated Hospital of Nanchang University
OTHER
Henan Cancer Hospital
OTHER_GOV
Second Xiangya Hospital of Central South University
OTHER
Tongji Hospital
OTHER
Institute of Hematology & Blood Diseases Hospital, China
OTHER